<DOC>
	<DOCNO>NCT00006396</DOCNO>
	<brief_summary>The purpose study see nevirapine ( NVP ) zidovudine ( AZT ) , give mother labor delivery baby first week life , reduce rate mother pass HIV baby . About 25 percent HIV-infected mother pass HIV infection baby labor delivery . There urgent need find simple way prevent mother-to-infant transmission labor delivery . The propose NVP schedule simpler possibly could use Uganda .</brief_summary>
	<brief_title>Effectiveness AZT Nevirapine Preventing HIV Transmission From Ugandan Mothers Their Newborns</brief_title>
	<detailed_description>There urgent need find safe , effective mean prevent mother-to-infant HIV transmission would also applicable affordable developing-country setting . The frequency vertical HIV-1 transmission estimate 25 percent . The propose trial specifically test hypothesis chemoprophylaxis fetus/neonate labor delivery first week life may significantly reduce risk perinatal HIV-1 transmission . Pregnant woman infect HIV-1 randomize 1 4 study arm receive either NVP placebo , AZT placebo . Mothers NVP group receive single dose NVP placebo onset labor follow 6 8 week delivery . Infants born mother receive 48 72 hour post-delivery discharge , whichever come first , regimen treatment ( NVP placebo ) give mother . Infants follow 18 month post-delivery clinical laboratory evaluation determine toxicity , evidence HIV-1 infection , clinical disease progression . Mothers AZT group receive either bolus AZT placebo onset labor , dose every 3 hour delivery , follow-up 6 8 week . Infants begin receive either low dose AZT placebo soon tolerate liquid mouth , twice daily 7 day , follow 18 month NVP group .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Mothers may eligible study : Have pregnant 32 week least 18 year age . Are HIVpositive . Reside within 15 km Mulago Hospital , study site . Infants may eligible study : Are born mother enrol study . Have consent mother/guardian , available , father . Exclusion Criteria Mothers eligible study : Have serious infection illness HIV . Currently take antiHIV drug . Participate pregnancy another treatment vaccine perinatal trial . Received NVP AZT within last 6 month . Are allergic benzodiazepine . Abuse alcohol drug . Have high blood pressure control . Have receive anticoagulant , benzodiazepine study drug , magnesium sulfate within 2 week assign study group delivery . Infants eligible study : Their mother exclude prior assign study group .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Pregnancy Complications , Infectious</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Disease Transmission , Vertical</keyword>
	<keyword>Enzyme-Linked Immunosorbent Assay</keyword>
	<keyword>Blotting , Western</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>